Barclays Maintains an 'Equalweight' on Edwards Lifesciences (EW); Table Set for Eventful 2012

Barclays maintains an 'Equalweight' on Edwards Lifesciences (NYSE: EW) price target of $80.00.

Barclays analyst, Matthew Taylor, said, "EW unveiled 2012 guidance at its 12/9/11 Analyst Day and gave some interesting incremental information around its TAVR program and expectations. Net-net, while we were intrigued by EW's new 14F valves, the meeting did not change our view on the stock, which we continue to think will be range bound as the company works toward FDA approval for Cohort A and a CMS NCD. EW guided to 2012 revenue of $1.95-$2.05 B (up 18-22%) versus consensus of $2.01B, and EPS of $2.70-$2.80 (up 35-40%) versus consensus of $2.78. US TAVR sales are anticipated in the range of $200-260 MM in 2012, driven by a 1Q12 FDA panel and mid-2012 approval for Partner's Cohort A."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $67.85 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• DA Davidson Reiterates Neutral Rating on Timken (TKR)
• UBS Reiterates Buy Rating on HF Sinclair (DINO)